MHRA authorises plozasiran for familial chylomicronaemia syndrome in UK adults
Start here
The UK's MHRA has authorised plozasiran, marketed as Redemplo, for adults with familial chylomicronaemia syndrome, a rare genetic disorder of triglyceride metabolism. The authorisation, granted on 19 October 2026, marks the arrival of a targeted RNA-based therapeutic option for a condition that has historically been managed with strict dietary fat restriction. As of now, the approval stands as a UK regulatory decision; questions that remain open include how quickly patients will access the drug in practice, its uptake across the NHS, and whether other regulators follow the MHRA's lead.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- gov.ukPickMHRA authorises plozasiran (Redemplo) for adults with familial chylomicronaemia syndrome
The UK MHRA authorised plozasiran (Redemplo) on 19 October 2026 for adults with familial chylomicronaemia syndrome. Original link: https://gov.uk/government/news/mhra-authorises-plozasiran-redemplo-for-adults-with-familial-chylomicronaemia-syndrome
Coverage and heat for this story
Reports so far 1·Heat now 6·Peak heat 10 (Oct 20 01:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.